Go Pro
→ Man who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown” (From Paradigm Press) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Endonovo Therapeutics, Inc. stock logo
ENDVD
Endonovo Therapeutics
$0.00
$1.10
▼
$37.90
$1.52M1.9811,850 shs500,000 shs
Gelteq Limited stock logo
GELS
Gelteq
$0.89
+27.6%		$0.59
$0.39
▼
$2.02
$7.50M-0.413.60 million shs69.51 million shs
Integrated BioPharma Inc. stock logo
INBP
Integrated BioPharma
$0.18
$0.17
$0.14
▼
$0.42
$5.58M0.45,574 shsN/A
Heatwurx Inc. stock logo
PCSA
Heatwurx
$2.05
-2.4%		$2.22
$1.67
▼
$14.24
$5.81M0.9644,983 shs10,301 shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover
7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Endonovo Therapeutics, Inc. stock logo
ENDVD
Endonovo Therapeutics
0.00%0.00%0.00%0.00%-32.50%
Gelteq Limited stock logo
GELS
Gelteq
+27.60%+56.67%+67.39%+79.72%-20.25%
Integrated BioPharma Inc. stock logo
INBP
Integrated BioPharma
0.00%-4.76%+12.36%-0.39%-33.14%
Heatwurx Inc. stock logo
PCSA
Heatwurx
-2.38%-2.84%-3.30%-18.65%-56.31%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Endonovo Therapeutics, Inc. stock logo
ENDVD
Endonovo Therapeutics
$0.00
$1.10
▼
$37.90
$1.52M1.9811,850 shs500,000 shs
Gelteq Limited stock logo
GELS
Gelteq
$0.89
+27.6%		$0.59
$0.39
▼
$2.02
$7.50M-0.413.60 million shs69.51 million shs
Integrated BioPharma Inc. stock logo
INBP
Integrated BioPharma
$0.18
$0.17
$0.14
▼
$0.42
$5.58M0.45,574 shsN/A
Heatwurx Inc. stock logo
PCSA
Heatwurx
$2.05
-2.4%		$2.22
$1.67
▼
$14.24
$5.81M0.9644,983 shs10,301 shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover
7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Endonovo Therapeutics, Inc. stock logo
ENDVD
Endonovo Therapeutics
0.00%0.00%0.00%0.00%-32.50%
Gelteq Limited stock logo
GELS
Gelteq
+27.60%+56.67%+67.39%+79.72%-20.25%
Integrated BioPharma Inc. stock logo
INBP
Integrated BioPharma
0.00%-4.76%+12.36%-0.39%-33.14%
Heatwurx Inc. stock logo
PCSA
Heatwurx
-2.38%-2.84%-3.30%-18.65%-56.31%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Endonovo Therapeutics, Inc. stock logo
ENDVD
Endonovo Therapeutics
0.00
N/AN/AN/A
Gelteq Limited stock logo
GELS
Gelteq
1.00
SellN/AN/A
Integrated BioPharma Inc. stock logo
INBP
Integrated BioPharma
0.00
N/AN/AN/A
Heatwurx Inc. stock logo
PCSA
Heatwurx
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest ENDVD, INBP, GELS, and PCSA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/17/2026
Heatwurx Inc. stock logo
PCSA
Heatwurx
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
6/26/2026
Gelteq Limited stock logo
GELS
Gelteq
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
6/11/2026
Gelteq Limited stock logo
GELS
Gelteq
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
(Data available from 9/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Endonovo Therapeutics, Inc. stock logo
ENDVD
Endonovo Therapeutics
$170K0.00N/AN/A($0.59) per share0.00
Gelteq Limited stock logo
GELS
Gelteq
$110K86.97N/AN/A$1.08 per share0.83
Integrated BioPharma Inc. stock logo
INBP
Integrated BioPharma
$54.35M0.10$0.07 per share2.68$0.66 per share0.27
Heatwurx Inc. stock logo
PCSA
Heatwurx
N/AN/AN/AN/A($0.11) per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Endonovo Therapeutics, Inc. stock logo
ENDVD
Endonovo Therapeutics
-$400K-$10.00N/AN/AN/A-6,075.54%N/A-279.35%N/A
Gelteq Limited stock logo
GELS
Gelteq
-$4.30MN/AN/AN/AN/AN/AN/AN/AN/A
Integrated BioPharma Inc. stock logo
INBP
Integrated BioPharma
$810K-$0.07N/AN/AN/A-3.43%-8.32%-6.57%N/A
Heatwurx Inc. stock logo
PCSA
Heatwurx
-$13.56M-$4.23N/AN/AN/AN/A-394.25%-244.46%10/29/2026 (Estimated)

Latest ENDVD, INBP, GELS, and PCSA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2026Q2 2026
Heatwurx Inc. stock logo
PCSA
Heatwurx
-$1.00-$1.19-$0.19-$1.19N/AN/A
6/30/2026Q2 2026
Gelteq Limited stock logo
GELS
Gelteq
N/A-$0.12N/A-$0.12N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Endonovo Therapeutics, Inc. stock logo
ENDVD
Endonovo Therapeutics
N/AN/AN/AN/AN/A
Gelteq Limited stock logo
GELS
Gelteq
N/AN/AN/AN/AN/A
Integrated BioPharma Inc. stock logo
INBP
Integrated BioPharma
N/AN/AN/AN/AN/A
Heatwurx Inc. stock logo
PCSA
Heatwurx
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Endonovo Therapeutics, Inc. stock logo
ENDVD
Endonovo Therapeutics
N/AN/AN/A
Gelteq Limited stock logo
GELS
Gelteq
N/A
0.09
N/A
Integrated BioPharma Inc. stock logo
INBP
Integrated BioPharma
N/A
3.25
1.78
Heatwurx Inc. stock logo
PCSA
Heatwurx
N/A
0.87
0.87

Institutional Ownership

CompanyInstitutional Ownership
Endonovo Therapeutics, Inc. stock logo
ENDVD
Endonovo Therapeutics
N/A
Gelteq Limited stock logo
GELS
Gelteq
N/A
Integrated BioPharma Inc. stock logo
INBP
Integrated BioPharma
25.25%
Heatwurx Inc. stock logo
PCSA
Heatwurx
91.93%

Insider Ownership

CompanyInsider Ownership
Endonovo Therapeutics, Inc. stock logo
ENDVD
Endonovo Therapeutics
5.61%
Gelteq Limited stock logo
GELS
Gelteq
N/A
Integrated BioPharma Inc. stock logo
INBP
Integrated BioPharma
67.40%
Heatwurx Inc. stock logo
PCSA
Heatwurx
3.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Endonovo Therapeutics, Inc. stock logo
ENDVD
Endonovo Therapeutics
147,0001.23 millionN/ANot Optionable
Gelteq Limited stock logo
GELS
Gelteq
N/A10.71 millionN/AN/A
Integrated BioPharma Inc. stock logo
INBP
Integrated BioPharma
15030.98 million10.10 millionNot Optionable
Heatwurx Inc. stock logo
PCSA
Heatwurx
202.77 million2.67 millionNot Optionable

Recent News About These Companies

Processa Pharmaceuticals to Participate in Upcoming Investor Conferences
September 1 at 7:00 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/01/3353972/0/en/processa-pharmaceuticals-to-participate-in-upcoming-investor-conferences.html
Processa Pharmaceuticals, Inc. (PCSA) M&A Call Prepared Remarks Transcript
July 29, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4927273-processa-pharmaceuticals-inc-pcsa-m-and-a-call-prepared-remarks-transcript
PROCESSA PHARMACEUTICALS, INC. ANNOUNCES ACQUISITION OF VIDYA THERAPEUTICS, INC.
July 29, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/29/3335130/0/en/processa-pharmaceuticals-inc-announces-acquisition-of-vidya-therapeutics-inc-and-approximately-200-million-concurrent-private-placement-to-advance-btk-inhibitor-vt-7208-in-multiple.html
Processa Pharmaceuticals to Attend 44th Annual J.P. Morgan Healthcare Conference
January 12, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/01/12/3217020/0/en/processa-pharmaceuticals-to-attend-44th-annual-j-p-morgan-healthcare-conference.html
Processa Pharmaceuticals Completes Enrollment of 20th Patient for Formal Interim Analysis in Phase 2 NGC-Cap Breast Cancer Study
January 5, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/01/05/3212860/0/en/processa-pharmaceuticals-completes-enrollment-of-20th-patient-for-formal-interim-analysis-in-phase-2-ngc-cap-breast-cancer-study.html
PCSA Stock Soars on Upbeat Clinical Update From Breast Cancer Study
December 18, 2025  |  zacks.comhttps://www.zacks.com/stock/news/2806083/pcsa-stock-soars-on-upbeat-clinical-update-from-breast-cancer-study?cid=cs-stocknewsapi-ft-analyst_blog|company_news_medical_sector-2806083
Processa Pharmaceuticals Provides Clinical Update on Phase 2 Study in Metastatic Breast Cancer
December 17, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/12/17/3206931/0/en/processa-pharmaceuticals-provides-clinical-update-on-phase-2-study-in-metastatic-breast-cancer.html
Processa Pharmaceuticals Announces Poster Presentation of Adaptive Phase 2/3 PCS499 Study in FSGS at ASN Kidney Week 2025
November 5, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/11/05/3181589/0/en/processa-pharmaceuticals-announces-poster-presentation-of-adaptive-phase-2-3-pcs499-study-in-fsgs-at-asn-kidney-week-2025.html
Processa Pharmaceuticals Secures Strategic Investment and Evaluates Corporate Crypto Treasury Strategies
August 7, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/08/07/3129263/0/en/processa-pharmaceuticals-secures-strategic-investment-and-evaluates-corporate-crypto-treasury-strategies.html
Processa Pharmaceuticals Provides Portfolio and Business Update
July 1, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/07/01/3108392/0/en/processa-pharmaceuticals-provides-portfolio-and-business-update.html
Processa Pares Gains on Equity Offer News
June 17, 2025  |  marketwatch.comhttps://www.marketwatch.com/story/processa-pares-gains-on-equity-offer-news-3b7edf2c
Processa Pharmaceuticals Announces Pricing of $7 Million Public Offering
June 17, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/06/17/3100974/0/en/processa-pharmaceuticals-announces-pricing-of-7-million-public-offering.html
Processa Pharmaceuticals Enters Exclusive Licensing Agreement with Intact Therapeutics for PCS12852, Potential Treatment for Gastroparesis
June 17, 2025  |  quiverquant.comQ
Processa Pharmaceuticals Signs Binding Term Sheet Granting Intact Therapeutics Exclusive Option to License Phase 2 Gastroparesis Drug Candidate
June 17, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/06/17/3100689/0/en/processa-pharmaceuticals-signs-binding-term-sheet-granting-intact-therapeutics-exclusive-option-to-license-phase-2-gastroparesis-drug-candidate.html
Processa Pharmaceuticals to Showcase Next Generation Cancer Therapies at 2025 BIO International Convention
June 15, 2025  |  nasdaq.comhttps://www.nasdaq.com/articles/processa-pharmaceuticals-showcase-next-generation-cancer-therapies-2025-bio-international
Processa Pharmaceuticals to Engage Potential Partners and Investors at BIO International Convention 2025
June 13, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/06/13/3098971/0/en/processa-pharmaceuticals-to-engage-potential-partners-and-investors-at-bio-international-convention-2025.html
Processa Pharmaceuticals Announces Presentation and Publication of Three Abstracts at 2025 ASCO Annual Meeting
May 30, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/05/30/3091075/0/en/processa-pharmaceuticals-announces-presentation-and-publication-of-three-abstracts-at-2025-asco-annual-meeting.html
Processa Pharmaceuticals’ Dr. David Young to Present at World Orphan Drug Congress USA 2025
April 15, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/processa-pharmaceuticals-dr-david-young-to-present-at-world-orphan-drug-congress-usa-2025-1034584299
Processa Pharmaceuticals' Dr. David Young to Present at World Orphan Drug Congress USA 2025
April 15, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/04/15/3061670/0/en/processa-pharmaceuticals-dr-david-young-to-present-at-world-orphan-drug-congress-usa-2025.html
Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference
March 18, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/03/18/3044510/0/en/processa-pharmaceuticals-to-present-at-the-medinvest-biotech-and-pharma-investor-conference.html

Media Sentiment Over Time

Endonovo Therapeutics stock logo

Endonovo Therapeutics OTCMKTS:ENDVD

Endonovo Therapeutics, Inc. is a biotechnology company, which engages in the development of bio-electronic approach to regenerative medicine. The firm also develops, manufactures and distributes evolutionary medical devices focused on the healing of wounds and reduction of pain, edema and inflammation on and in the human body. Its technology and products include Electroceuticals, EFECT Trial, SofPulse, Electroceutical Therapy, and Scientific Studies. The company was founded in November 2008 and is headquartered in Woodland Hills, CA.

Gelteq stock logo

Gelteq NASDAQ:GELS

$0.89 +0.19 (+27.60%)
Closing price 09/3/2026 04:00 PM Eastern
Extended Trading
$0.81 -0.08 (-9.20%)
As of 08:27 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Gelteq Inc. is a biotechnology company which specializes in the formulation, development and manufacturing of ingestible gel platform designed for nutrient and drug delivery. The Company is focused on advancing and commercializing its delivery solutions within core verticals pharmaceuticals, over-the-counter medications, nutraceuticals, animal medications and sports nutrition. Gelteq Inc. is based in NEW YORK.

Integrated BioPharma stock logo

Integrated BioPharma OTCMKTS:INBP

$0.18 0.00 (0.00%)
As of 09/2/2026

Integrated BioPharma, Inc., together with its subsidiaries, manufactures, distributes, markets, and sells vitamins, nutritional supplements, and herbal products primarily in the United States and Luxembourg. It operates through Contract Manufacturing and Other Nutraceutical Businesses segments. The Contract Manufacturing segment manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers, and specialized health-care providers. The Other Nutraceutical Businesses segment distributes healthful nutritional products for sale through mass market, grocery, drug, and vitamin retailers under the Peaceful Sleep and Wheatgrass brands, as well as other branded proprietary nutraceutical products. This segment also sells private label vitamin and nutritional supplement products through the Internet; provides warehousing and fulfilment services; and distributes fine natural botanicals, including multi minerals, as well as raw materials. The company was formerly known as Integrated Health Technologies, Inc. Integrated BioPharma, Inc. was incorporated in 1980 and is based in Hillside, New Jersey.

Heatwurx stock logo

Heatwurx NASDAQ:PCSA

$2.05 -0.05 (-2.38%)
Closing price 09/3/2026 04:00 PM Eastern
Extended Trading
$2.05 0.00 (0.00%)
As of 06:51 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine that has completed Phase 1b clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers. It also develops non-oncology drugs consisting of PCS12852 for treatment of gastroparesis; and PCS499 to treat patients with ulcerative and non-ulcerative necrobiosis lipoidica. The company has license agreements with Elion Oncology, Inc.; Ocuphire Pharma, Inc.; Aposense, Ltd.; Yuhan Corporation; and CoNCERT Pharmaceuticals, Inc. Processa Pharmaceuticals, Inc. was founded in 2011 and is based in Hanover, Maryland.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas